BT2

Overview

BT2 is a BCKDC kinase (BDK) inhibitor with an IC 50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC). BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a K i value of 59 μM.

Application

Products | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Bcl-2 Family

Product Information

• Catalog No.: HY-114855
• CAS No.: 34576-94-8
• Molecular Formula: C9H4Cl2O2S
• Molecular Weight: 247.10
• Purity: 99.81%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (8.42 mM); Clear solution
• Availability: In-stock

Source

Original product source